WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, will release its financial results for the fourth
quarter and full year 2013 on Thursday, February 27, 2014.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, February 27, 2014 to discuss its fourth quarter and full year
2013 financial results. A live webcast of the conference call will be
available online from the investor relations page of AtriCure’s
corporate website at www.atricure.com.
Pre-registration is available and recommended for this call at the
You may also access this call through an operator by calling (888)
713-4214 for domestic callers and (617) 213-4866 for international
callers at least 15 minutes prior to the call start time using
reservation code 59283031.
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will also be available through March 27, 2014. The
replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
801-6888 for international callers. The reservation code is 68935249.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in
patients undergoing certain open concomitant procedures. AtriCure’s
AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely
implanted device for LAA management worldwide. The company believes
cardiothoracic surgeons are adopting its ablation and LAA management
devices for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 5.5 million people
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief Financial